Trial Profile
A retrospective trial evaluating the effects of alemtuzumab versus antithymocyte globulin in highly sensitized kidney transplant patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 04 Nov 2015 New trial record
- 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation